Investor Presentation First Nine Months of 2022
48
Investor presentation
First nine months of 2022
Novo NordiskⓇ
A fixed dose combination with GIP entered phase 2 in the second
half of 2021 in people with type 2 diabetes
Phase 2 trial design for semaglutide in combination with GIP
N = ~500
Dose ratio 1:1 Semaglutide QW + GIP QW
Placebo
Dose ratio 1:3 Semaglutide QW + GIP QW
Placebo
Dose ratio 1:5 Semaglutide QW + GIP QW
Placebo
Dose ratio 1:9 Semaglutide + GIP QW
Placebo
GIP QW
Semaglutide QW
K
Dose escalation
10 weeks
Maintenance period
24 weeks
FU 5
weeks
Inclusion criteria:
•
Age ≥ 18-75 years
•
.
• BMI: 25-39.9 kg/m2
HbA1c: 7.0-10.0%
Diet/exercise + metformin
Type 2 diabetes
Objective
Compare the effect on glycaemic control and body weight of semaglutide
in combination with GIP vs semaglutide and vs GIP
Primary endpoint
Change from baseline to week 34 in HbA1c (%-point)
Trial start
39-week trial was initiated in Q4 2021
T2D: Type 2 diabetes; HbA₁: Hemoglobin A1c; BMI: Body mass index; FU: Follow-up; OAD: Oral anti-diabetic; GIP: Gastric inhibitory peptide; QW: Once-weeklyView entire presentation